Skip to content
Clinical Trials – home

Find therapies in clinical trials near you – page 88

recruiting
3 972
countries
28
conditions
2 103

1 088 trials match your criteria

Haemophilia

Not recruiting

Study on Fitusiran for Preventing Bleeding in Males Aged 12 and Older with Severe Hemophilia A or B, with or without Inhibitors

Registered drugNo placebo
Countries:GreeceGreece
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Fitusiran

Study Comparing Pembrolizumab and Lenvatinib with Docetaxel for Patients with Metastatic Non-Small Cell Lung Cancer After Previous Treatments

Registered drugNo placebo
Countries:GreeceGreece
  • Participants:18–64 years · 65+ years
  • Substances:Lenvatinib

Study on Milvexian for Preventing Stroke in Patients with Acute Ischemic Stroke or High-Risk Transient Ischemic Attack

Registered drug
Countries:GreeceGreece
  • Participants:18–64 years · 65+ years
  • Substances:Acetylsalicylic Acid

Study comparing tarlatamab with topotecan in patients with relapsed small cell lung cancer after first-line chemotherapy

Registered drugNo placebo
Countries:GreeceGreece
  • Participants:18–64 years · 65+ years
  • Substances:Ammonium Chloride

Thalassaemia alpha

Not recruiting

Study on Luspatercept for Treating Anemia in Adults and Adolescents with Alpha-Thalassemia

Registered drug
Countries:GreeceGreece
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Luspatercept

Bladder cancer

Not recruiting

Study of Pembrolizumab, Vibostolimab, and Favezelimab for Patients with High-Risk Non-Muscle Invasive Bladder Cancer Unresponsive to BCG Therapy

Registered drugNo placebo
Countries:GreeceGreece
  • Participants:18–64 years · 65+ years
  • Substances:Favezelimab

Open angle glaucoma+2

Not recruiting

Study on the Effectiveness of Citicoline Eye Drops for Visual Field Preservation in Patients with Open Angle Glaucoma

Investigational
Countries:GreeceGreece
  • Participants:18–64 years · 65+ years
  • Substances:Citicoline Sodium

Study on Luspatercept and Epoetin Alfa for Treating Anemia in Patients with Low to Intermediate Risk Myelodysplastic Syndromes Needing Blood Transfusions

Registered drugNo placebo
Countries:GreeceGreece
  • Participants:18–64 years · 65+ years
  • Substances:Epoetin Alfa

Type 2 diabetes mellitus+3

Not recruiting

Evaluating Once Daily Orforglipron (LY3502970) Compared to Insulin Glargine in Adults with Type 2 Diabetes and Obesity or Overweight who Have Increased Cardiovascular Risk

Registered drugNo placebo
Countries:GreeceGreece
  • Participants:18–64 years · 65+ years
  • Substances:Canagliflozin

Endometrial cancer

Not recruiting

Study of Pembrolizumab with Chemotherapy for High-Risk Endometrial Cancer Patients After Surgery

Registered drug
Countries:GreeceGreece
  • Participants:18–64 years · 65+ years
  • Substances:Anhydrous Docetaxel

Marginal zone lymphoma+1

Not recruiting

Study Comparing Zanubrutinib, Obinutuzumab, and Rituximab with Lenalidomide and Rituximab for Patients with Relapsed or Refractory Follicular or Marginal Zone Lymphoma

Registered drugNo placebo
Countries:GreeceGreece
  • Participants:18–64 years · 65+ years
  • Substances:Lenalidomide

Hidradenitis

Not recruiting

Study on the Effects and Safety of SAR442970 for Adults with Moderate to Severe Hidradenitis Suppurativa

Investigational
Countries:GreeceGreece
  • Participants:18–64 years · 65+ years
  • Substances:SAR442970
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.